VA sites in validation study; SAB appointment
LungLife AI, Inc.
(the "Company" or "LungLife")
Veterans Affairs (VA) sites added to validation study with first Veteran enroled
Key lung cancer specialist, Dr Drew Moghanaki, appointed to Scientific Advisory Board
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its pivotal clinical study to evaluate the LungLB® test will now include multiple VA medical centres, of which the first participant has been enroled from the Bay Pines VA in Florida.
The VA has the United States' largest integrated health care system, providing care at nearly 1,300 facilities and serving 9 million veterans each year. Lung cancer is the leading cause of cancer-related deaths among US veterans, and it is believed that veterans are at higher risk in part due to environmental exposures during military service. An estimated 900,000 US veterans are at-risk for lung cancer, and VA hospitals diagnose around 7,700 new lung cancer cases each year.
The Company also announces the appointment of Dr Drew Moghanaki, MD, MPH, to its Scientific Advisory Board, who is an internationally recognised lung cancer specialist. He is Professor and Chief of Thoracic Oncology at the UCLA Department of Radiation Oncology. Dr Moghanaki brings extensive leadership to the Scientific Advisory Board as the Director of the VA Partnership to increase Access to Lung Cancer Screening programme (VA-PALS), and the co-chair of the VA Lung Cancer Surgery or Stereotactic Radiotherapy (VALOR) Phase III study, investigating treatment options for stage I lung cancer. Dr Moghanaki is also Staff Physician at the Greater Los Angeles VA Healthcare System.
Dr Drew Moghanaki, MD, MPH, Scientific Advisory Board member at LungLife, said: "Blood-based testing to facilitate early detection of lung cancer would be a welcomed advance as the majority of lung cancers continue to be diagnosed in later stages. I am pleased to be joining LungLife's Scientific Advisory Board and look forward to working with them to unlock the full potential of the LungLB® test."
Paul Pagano, Chief Executive Officer of LungLife, said : "I am delighted that we will have representation from the VA Healthcare System in our study, as this marks an important step on our journey towards the successful deployment of the LungLB® test. Dr Moghanaki brings with him significant experience in early detection and treatment of lung cancer which will further strengthen our Scientific Advisory Board."
For further information please contact:
|
LungLife AI, Inc. |
|
|
Paul Pagano, CEO |
Via Walbrook PR |
|
David Anderson, CFO |
|
|
|
|
|
Investec Bank plc (Nominated Adviser & Broker) |
Tel: +44 (0)20 7597 5970 |
|
Daniel Adams / Virginia Bull / Cameron MacRitchie |
|
|
|
|
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com |
|
Paul McManus / Alice Woodings / Phillip Marriage |
Mob: 07980 541 893 / 07407 804 654 / 0 7867 984 082 |
About Lunglife AI
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 2 days ago City of London Investment Group
- 2 days ago Aberdeen Group plc
- 2 days ago NATWEST GROUP
- 2 days ago Ondo Insurtech
- 2 days ago Banco Santander S.A.